HDT 321
Alternative Names: HDT-321Latest Information Update: 15 Dec 2022
At a glance
- Originator HDT Bio; University of Texas Medical Branch
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Crimean-Congo haemorrhagic fever virus infections
Most Recent Events
- 05 Dec 2022 Early research in Crimean-Congo haemorrhagic fever virus infections (Prevention) in USA (Parenteral)
- 01 Dec 2022 HDT Bio in collaboration with the University of Texas Medical Branch receives BARDA grant from the US government for HDT 321 development in Congo hemorrhagic fever virus infections